


PRESTA Study Results



OVERVIEW:

This randomised, multicentre study enrolled patients with both psoriasis and psoriatic arthritis from 110 global sites. In the double-blind period, patients received either Enbrel 50mg twice weekly (BiW) or 50mg once-weekly (QW) for 12 weeks; in the subsequent open-label period, patients received 50mg once weekly for 12 weeks.

Results showed:



	% Patients				P-value	
	ETN 50 mg BiW/QW		ETN 50 mg QW		Wk 12	Wk 24
PASI	Wk 12	Wk 24	Wk 12	Wk 24	Wk 12	Wk 24
≥50%	80	86	74	83	0.049	0.185
≥75%	55	70	36	62	<0.001	0.026
≥90%	27	46	15	35	<0.001	0.002
PsARC	76	77	72	75	0.264	0.722



DERMATOLOGY LIFE QUALITY INDEX (DLQI):

Results from the quality of life investigation showed:

- The mean Dermatology Life Quality Index (DLQI) total score was 12 for both Enbrel groups – a substantially reduced quality of life at baseline.
- At week 12, the 50mg twice-weekly (BiW) group had a mean DLQI of 4.42, and the 50mg once-weekly (QW) group had a mean DLQI of 5.47, representing a significant improvement after only 12 weeks, and sustained over 24 weeks.

